Month: July 2021

Artelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update

Written by Customer Service on July 12, 2021. Posted in Earnings Releases And Operating Results.

Enrollment in CAReS Study in patients with cancer anorexia on track to deliver first data readout by calendar year-end $10.0 Million of Cash and Cash Equivalents as of May 31, 2021 SOLANA BEACH, Calif., July 12, 2021 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the third fiscal 2021 quarter ended May 31, 2021 and provided a business update. “We are making substantial progress enrolling patients in the ongoing Phase 1/2 Cancer Appetite Recovery Study (CAReS) of our lead drug candidate, ART27.13,” stated, Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “ART27.13 represents a...

Reporting of Director’s transaction in Bang & Olufsen shares

Written by Customer Service on July 12, 2021. Posted in Public Companies.

Bang & Olufsen A/S has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transaction related to shares in Bang & Olufsen A/S made by persons discharging managerial responsibilities in Bang & Olufsen A/S and/or persons closely related with them. Please see attached file for details. For further information, please contact: Director, Investor Relations, Martin Raasch Egenhardt, phone: +45 5370 7439.AttachmentBO_2106_Director’s share transactions_UK

Abaxx and ACX to host SmarterMarkets™ webcast on Scaling Voluntary Carbon Markets

Written by Customer Service on July 12, 2021. Posted in Public Companies.

TORONTO, July 12, 2021 (GLOBE NEWSWIRE) — Abaxx Technologies Inc., (NEO:ABXX) (OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial technology (fintech) company, majority shareholder of Abaxx Singapore Pte. Ltd., the Abaxx Commodity Exchange, and producer of the SmarterMarkets™ Podcast, will participate in a SmarterMarkets™ public webcast to discuss emerging trends in voluntary carbon-offset markets following a recent framework report published on July 8 2021 by the Mark Carney-led Taskforce on Scaling Voluntary Carbon Market (“TSVCM”). SmarterMarkets™ will host the webcast with Zoom webinars (login details below), inviting Abaxx shareholders and general market participants who are interested to learn more about the rapidly evolving market opportunity for voluntary carbon offsets. The webinar will feature industry leading experts...

Inotiv Acquires Genetic Toxicology Assets from MilliporeSigma’s BioReliance® portfolio

Written by Customer Service on July 12, 2021. Posted in Mergers And Acquisitions.

WEST LAFAYETTE, Ind., July 12, 2021 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, today announced that the Company has acquired key genetic toxicology assets from MilliporeSigma’s BioReliance® portfolio, including standard operating procedures, stock cultures, historic control data and client list. While Inotiv did not disclose the specific financial terms, the transaction consists of a sales-based royalty agreement and does not require upfront funding from the Company. Robert Leasure, Jr., President and CEO of Inotiv, commented, “This transaction with MilliporeSigma adds genetic toxicology to our suite of internal capabilities. We now have assembled in-house all...

Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole

Written by Customer Service on July 12, 2021. Posted in Public Companies.

Data Additionally include Potential Benefit for the Control of Antimicrobial Resistance and a Novel Mechanism of Action Cambridge, MA, July 12, 2021 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) is today displaying three preeminent ePosters at the prestigious 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). Two ePosters bring increased awareness and understanding of the significance of data generated using shotgun metagenomic analyses to compare ridinilazole and vancomycin treated patients with Clostridioides difficile infection (CDI) from our Phase II CoDIFy clinical trial. Vancomycin, discovered in the 1950’s, is the current standard of care for the treatment of C. difficile infection. Highlights of the ePosters include data demonstrating the relative...

Lakeland Bancorp, Inc. to Acquire 1st Constitution Bancorp

Written by Customer Service on July 12, 2021. Posted in Mergers And Acquisitions.

OAK RIDGE, N.J. and CRANBURY, N.J., July 12, 2021 (GLOBE NEWSWIRE) — The Boards of Directors of Lakeland Bancorp, Inc. (“Lakeland”) (NASDAQ: LBAI), the parent company of Lakeland Bank, and 1st Constitution Bancorp (“1st Constitution”) (NASDAQ: FCCY), the parent company of 1st Constitution Bank, announced today that they have entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”), under which Lakeland will acquire 1st Constitution. The combined organization will have approximately $9.6 billion in assets and will rank as the 5th largest bank headquartered in New Jersey. The merger brings together two high-performing companies with complementary geographies and business lines. Lakeland will acquire all of the outstanding shares of 1st Constitution in exchange for common shares of Lakeland and will cash out...

Osisko Announces Preliminary Q2 2021 Deliveries and Provides Asset Update

Written by Customer Service on July 12, 2021. Posted in Earnings Releases And Operating Results.

Figure 1.Composites long section from Agnico Eagle’s July 8th, 2021 press release showing exploration highlights on the East Gouldie deposit and new discovery (RD20-4674).MONTREAL, July 12, 2021 (GLOBE NEWSWIRE) — Osisko Gold Royalties Ltd (the “Corporation” or “Osisko”) (OR: TSX & NYSE) is pleased to provide an update on its second quarter deliveries, sales and operating cash margins1 and recent asset advancements. PRELIMINARY Q2 2021 RESULTS Osisko earned approximately 20,178 attributable gold equivalent ounces2 (“GEOs”) in the second quarter of 2021, excluding GEOs earned from the Renard diamond stream. Osisko recorded preliminary revenues3 of C$57.2 million during the second quarter and preliminary cost of sales3 (excluding depletion) of C$10.1 million, resulting in a record operating cash margin1 of...

HCI Group Declares Q3 2021 Quarterly Cash Dividend

Written by Customer Service on July 12, 2021. Posted in Dividend Reports And Estimates.

TAMPA, Fla., July 12, 2021 (GLOBE NEWSWIRE) — The board of directors of HCI Group, Inc. (NYSE:HCI), a holding company with operations in homeowners insurance, software development, and real estate, has declared a regular quarterly cash dividend in the amount of 40 cents per common share for the third quarter of 2021. The dividend will be paid September 17, 2021 to shareholders of record at the close of business August 20, 2021. About HCI Group, Inc.HCI Group, Inc. owns subsidiaries engaged in diverse, yet complementary business activities, including homeowners insurance, reinsurance, real estate and information technology services. HCI’s leading insurance operation, TypTap Insurance Company, is a rapidly growing, technology-driven insurance company that is expanding nationwide to provide homeowners and flood insurance. TypTap’s...

Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021

Written by Customer Service on July 12, 2021. Posted in Public Companies.

NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) — Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that Chief Executive Officer Howard J. Federoff, M.D., Ph.D., will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 – 15, 2021. Dr. Federoff will deliver his corporate presentation on July 15 at 9:00am ET. To receive additional information, request an invitation or to schedule a one-on-one meeting, please email angie.goertz@issuerdirect.com. Investors can register here. About Brooklyn ImmunoTherapeuticsBrooklyn is focused on exploring the role that cytokine-based...

Nemaura Medical to Present at the Access to Giving Virtual Investor Conference on July 13, 2021

Written by Customer Service on July 12, 2021. Posted in Public Companies.

Loughborough, England, July 12, 2021 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that Chief Executive Officer Faz Chowdhury, Ph.D. will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 – 15, 2021. Dr. Chowdhury will deliver his corporate presentation on July 13 at 1:00pm ET. To receive additional information, request an invitation or to schedule a one-on-one meeting, please email angie.goertz@issuerdirect.com. Investors can register here. About Nemaura Medical, Inc. Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic...

Month: July 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals